588 related articles for article (PubMed ID: 28668966)
1. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
2. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
3. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
4. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Liu Y; Xu N; Liu B; Huang Y; Zeng H; Yang Z; He Z; Guo H
Oncotarget; 2016 Jul; 7(28):43835-43851. PubMed ID: 27270310
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
7. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
8. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
9. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Zhou D; Wan Y; Xie D; Wang Y; Wei J; Yan Q; Lu P; Mo L; Xie J; Yang S; Qi X
Exp Mol Med; 2015 Sep; 47(9):e182. PubMed ID: 26337869
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
Zeng H; Xu N; Liu Y; Liu B; Yang Z; Fu Z; Lian C; Guo H
Int J Oncol; 2017 Aug; 51(2):445-455. PubMed ID: 28714520
[TBL] [Abstract][Full Text] [Related]
11. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
13. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Fan TY; Wang H; Xiang P; Liu YW; Li HZ; Lei BX; Yu M; Qi ST
Int J Clin Exp Pathol; 2014; 7(10):6662-70. PubMed ID: 25400745
[TBL] [Abstract][Full Text] [Related]
15. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
16. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis.
Zhang S; Wang W; Liu G; Xie S; Li Q; Li Y; Lin Z
Biomed Pharmacother; 2017 Nov; 95():711-720. PubMed ID: 28886531
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Zhou B; Bu G; Zhou Y; Zhao Y; Li W; Li M
Med Oncol; 2015 Jan; 32(1):378. PubMed ID: 25433945
[TBL] [Abstract][Full Text] [Related]
20. LncRNA-XIST interacts with
Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]